Exercise training decreases Neuregulin-1 concentrations in HER2-positive breast cancer patients undergoing adjuvant trastuzumab: the CARDAPAC study.

Date publication

février 2026

Journal

Breast cancer research and treatment

Auteurs

Membres identifiés du Cancéropôle Est :
Dr MENEVEAU Nathalie , Dr MOUGIN-GUILLAUME Fabienne , Dr JACQUINOT Quentin , Mr FALCOZ Antoine

Tous les auteurs :
Jacquinot Q, Ennequin G, Falcoz A, Sawyer D, Meneveau N, Mougin F

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/41636910

Résumé

Trastuzumab used for the treatment of patients with HER2-positive breast cancer induces cardiotoxicity. The NRG1/HER pathway plays a central role in human cardiovascular physiology; however, the link between exercise, NRG1, and cardiotoxicity is unclear.

Mots clés

Breast cancer, Cardiotoxicity, Exercise, HER2 overexpression, Neuregulin, Prevention, Supervised exercise program, Supportive care

Référence

Breast Cancer Res Treat. 2026 02 4;215(3):69